NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free APLT Stock Alerts $4.31 -0.15 (-3.36%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$4.17▼$4.5650-Day Range$3.75▼$7.4052-Week Range$1.09▼$9.39Volume770,112 shsAverage Volume1.94 million shsMarket Capitalization$456.39 millionP/E RatioN/ADividend YieldN/APrice Target$11.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Applied Therapeutics alerts: Email Address Applied Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside155.2% Upside$11.00 Price TargetShort InterestHealthy4.70% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$2.47 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.53) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.49 out of 5 starsMedical Sector88th out of 907 stocksPharmaceutical Preparations Industry27th out of 421 stocks 4.5 Analyst's Opinion Consensus RatingApplied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApplied Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.70% of the outstanding shares of Applied Therapeutics have been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Applied Therapeutics has recently increased by 31.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApplied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Applied Therapeutics is -0.88. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 4 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,469,181.00 in company stock.Percentage Held by Insiders19.10% of the stock of Applied Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Applied Therapeutics are expected to grow in the coming year, from ($0.53) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Applied Therapeutics Stock (NASDAQ:APLT)Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More APLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLT Stock News HeadlinesApril 15, 2024 | americanbankingnews.comApplied Therapeutics, Inc. (NASDAQ:APLT) Short Interest UpdateApril 15, 2024 | globenewswire.comApplied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerApril 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 14, 2024 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)April 6, 2024 | investing.comApplied Therapeutics reveals Phase 3 data on heart drugApril 4, 2024 | finance.yahoo.comApplied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)April 1, 2024 | benzinga.comFDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare DiseaseApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.April 1, 2024 | benzinga.comWhy Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving PremarketMarch 29, 2024 | markets.businessinsider.comApplied Therapeutics Says FDA Extends Review Period Of NDA For GovorestatMarch 28, 2024 | finance.yahoo.comUPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drugMarch 28, 2024 | reuters.comUS FDA extends review of Applied Therapeutics' genetic disease drugMarch 28, 2024 | globenewswire.comApplied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaMarch 20, 2024 | investing.comApplied therapeutics CCO sells shares worth over $263kMarch 20, 2024 | investing.comApplied therapeutics CFO sells shares worth over $150kMarch 8, 2024 | finance.yahoo.comApplied Therapeutics Inc (APLT) Announces Year-End 2023 Financial Results and Clinical ProgressMarch 6, 2024 | globenewswire.comApplied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Applied Therapeutics as FDA Prioritizes Govorestat, Signaling Strong Market ProspectsMarch 1, 2024 | markets.businessinsider.comOptimistic Buy Rating for Applied Therapeutics Amid Favorable Drug Approval Prospects and Strong Financial PositionFebruary 28, 2024 | marketwatch.comApplied Therapeutics Shares Surge on FDA Review, $100 Million Funding RoundFebruary 28, 2024 | markets.businessinsider.comApplied Therapeutics Rallies After Announcing Private Placement Of SharesFebruary 28, 2024 | msn.comFDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic DisorderFebruary 28, 2024 | investorplace.comWhy Is Applied Therapeutics (APLT) Stock Up 59% Today?February 28, 2024 | globenewswire.comApplied Therapeutics Announces $100 Million Private PlacementFebruary 28, 2024 | globenewswire.comApplied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic GalactosemiaFebruary 24, 2024 | msn.comApplied Therapeutics (APLT) Price Target Increased by 20.65% to 9.44See More Headlines Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APLT CUSIPN/A CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees25Year Founded2017Price Target and Rating Average Stock Price Target$11.60 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+168.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,760,000.00 Net MarginsN/A Pretax Margin-1,198.47% Return on EquityN/A Return on Assets-275.83% Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual Sales$9.99 million Price / Sales45.79 Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-21.60Miscellaneous Outstanding Shares105,890,000Free Float85,663,000Market Cap$457.44 million OptionableOptionable Beta1.81 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Shoshana Shendelman Ph.D. (Age 45)Chair of the Board of Directors, Founder, President, CEO & Secretary Comp: $813.47kMr. Les D. Funtleyder (Age 53)CFO, Principal Financial Officer & Independent Director Comp: $40kDr. Riccardo Perfetti M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $858kMr. Adam Hansard (Age 47)Chief Commercial Officer Comp: $742.66kMr. Constantine Chinoporos (Age 58)COO & Chief Business Officer Ms. Catherine Thorpe (Age 60)Chief Accounting Officer More ExecutivesKey CompetitorsKalVista PharmaceuticalsNASDAQ:KALVFulcrum TherapeuticsNASDAQ:FULCOculisNASDAQ:OCSAdlai NortyeNASDAQ:ANLIGM BiosciencesNASDAQ:IGMSView All CompetitorsInsiders & InstitutionsDenali Advisors LLCBought 33,600 shares on 4/19/2024Ownership: 0.032%Shoshana ShendelmanSold 318,573 sharesTotal: $1.72 M ($5.39/share)Riccardo PerfettiSold 110,804 sharesTotal: $597,233.56 ($5.39/share)Leslie D FuntleyderSold 28,727 sharesTotal: $154,838.53 ($5.39/share)Opaleye Management Inc.Bought 199,500 shares on 2/15/2024Ownership: 1.415%View All Insider TransactionsView All Institutional Transactions APLT Stock Analysis - Frequently Asked Questions Should I buy or sell Applied Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APLT shares. View APLT analyst ratings or view top-rated stocks. What is Applied Therapeutics' stock price target for 2024? 5 brokerages have issued 12 month target prices for Applied Therapeutics' stock. Their APLT share price targets range from $7.00 to $13.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 155.2% from the stock's current price. View analysts price targets for APLT or view top-rated stocks among Wall Street analysts. How have APLT shares performed in 2024? Applied Therapeutics' stock was trading at $3.35 on January 1st, 2024. Since then, APLT stock has increased by 28.7% and is now trading at $4.31. View the best growth stocks for 2024 here. Are investors shorting Applied Therapeutics? Applied Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,980,000 shares, an increase of 31.4% from the March 15th total of 3,790,000 shares. Based on an average daily trading volume, of 2,070,000 shares, the short-interest ratio is presently 2.4 days. View Applied Therapeutics' Short Interest. When is Applied Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our APLT earnings forecast. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics, Inc. (NASDAQ:APLT) issued its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.18. The firm had revenue of ($0.67) million for the quarter. What ETF holds Applied Therapeutics' stock? Simplify Propel Opportunities ETF holds 2,817,505 shares of APLT stock, representing 14.71% of its portfolio. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and RTX (RTX). When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager. Who are Applied Therapeutics' major shareholders? Applied Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Denali Advisors LLC (0.03%). Insiders that own company stock include Charles Silberstein, Chids Mahadevan, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter. View institutional ownership trends. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APLT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
